CoChat

Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study

Open access

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Background: We aimed to predict response to biologics in inflammatory bowel disease (IBD) using computerized image analysis of probe confocal laser endomicroscopy (pCLE) in vivo and assess the binding of fluorescent-labeled biologics ex vivo. Additionally, we investigated genes predictive of anti-tumor necrosis factor (TNF) response. Methods: Twenty-nine patients (15 with Crohn’s disease [CD], 14 with ulcerative colitis [UC]) underwent colonoscopy with pCLE before and 12 to 14 weeks after starting anti-TNF or anti-integrin α4β7 therapy. Biopsies were taken for fluorescein isothiocyanate–labeled infliximab and vedolizumab staining and gene expression analysis. Computer-aided quantitative image analysis of pCLE was performed. Differentially expressed genes predictive of response were determined and validated in a public cohort. Results: In vivo, vessel tortuosity, crypt morphology, and fluorescein leakage predicted response in UC (area under the receiver-operating characteristic curve [AUROC], 0.93; accuracy 85%, positive predictive value [PPV] 89%; negative predictive value [NPV] 75%) and CD (AUROC, 0.79; accuracy 80%; PPV 75%; NPV 83%) patients. Ex vivo, increased binding of labeled biologic at baseline predicted response in UC (UC) (AUROC, 83%; accuracy 77%; PPV 89%; NPV 50%) but not in Crohn’s disease (AUROC 58%). A total of 325 differentially expressed genes distinguished responders from nonresponders, 86 of which fell within the most enriched pathways. A panel including ACTN1, CXCL6, LAMA4, EMILIN1, CRIP2, CXCL13, and MAPKAPK2 showed good prediction of anti-TNF response (AUROC >0.7). Conclusions: Higher mucosal binding of the drug target is associated with response to therapy in UC. In vivo, mucosal and microvascular changes detected by pCLE are associated with response to biologics in inflammatory bowel disease. Anti-TNF–responsive UC patients have a less inflamed and fibrotic state pretreatment. Chemotactic pathways involving CXCL6 or CXCL13 may be novel targets for therapy in nonresponders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ibd/izac233

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract Overview of the study methodology.
Graphical abstract Overview of the study methodology.CC BY · PubMed Central
Figure 1. Summary of probe confocal laser endomicroscopy findings in vivo and ex vivo.
Figure 1. Summary of probe confocal laser endomicroscopy findings in vivo and ex vivo.CC BY · PubMed Central
Figure 2. Immunohistochemistry for tumor necrosis factor (TNF) and integrin-β7 was performed on biopsies sampled before and after biologic treatment. Expression was scored on a scale of 0 to 3 in which 0 = none, 1 = low (<30%), 2 = medium (30%-60%), and 3 = high (>60%). A, Representative images of tissues with high and low expression. B, Summary of scores for tissues from patients classified as nonresponder (NR), partial responder (PR), and responder (R). i and ii indicate actual scores. iii and iv show reduction in score from pre- to posttreatment (pre score minus post score). Numbers indicate the number of patients represented where data points overlap.
Figure 2. Immunohistochemistry for tumor necrosis factor (TNF) and integrin-β7 was performed on biopsies sampled before and after biologic treatment. Expression was scored on a scale of 0 to 3 in which 0 = none, 1 = low (<30%), 2 = medium (30%-60%), and 3 = high (>60%). A, Representative images of tissues with high and low expression. B, Summary of scores for tissues from patients classified as nonresponder (NR), partial responder (PR), and responder (R). i and ii indicate actual scores. iii and iv show reduction in score from pre- to posttreatment (pre score minus post score). Numbers indicate the number of patients represented where data points overlap.CC BY · PubMed Central
Figure 3. A, A diagrammatic representation of the direction of regulation of the differentially expressed genes (DEGs) when partial responders are considered as responders. B, A principal component analysis score plot performed on the 342 DEGs demonstrating clustering of the responders vs nonresponders. Dots represent patients and are colored according to the subject cohort. Ellipses represent 95% confidence.
Figure 3. A, A diagrammatic representation of the direction of regulation of the differentially expressed genes (DEGs) when partial responders are considered as responders. B, A principal component analysis score plot performed on the 342 DEGs demonstrating clustering of the responders vs nonresponders. Dots represent patients and are colored according to the subject cohort. Ellipses represent 95% confidence.CC BY · PubMed Central
Figure 4. A selection of response predictive markers for anti-tumor necrosis factor (TNF) therapy. An area under the curve (AUC) analysis was performed on the enriched genes with variable importance in projection >1 that were also measured in the validation study. A, Heat map summaries of the 7 selected targets in the Crohn’s disease (CD)/ulcerative colitis (UC) and validation cohorts. B, Sensitivity vs specificity receiver-operating characteristic curves for combined use of CRIP2, CXCL6, EMILIN1, GADD45B, LAMA4, and MAPKAPK2 as predictors of TNF response in the optima cohort and validation cohorts. CI, confidence interval.
Figure 4. A selection of response predictive markers for anti-tumor necrosis factor (TNF) therapy. An area under the curve (AUC) analysis was performed on the enriched genes with variable importance in projection >1 that were also measured in the validation study. A, Heat map summaries of the 7 selected targets in the Crohn’s disease (CD)/ulcerative colitis (UC) and validation cohorts. B, Sensitivity vs specificity receiver-operating characteristic curves for combined use of CRIP2, CXCL6, EMILIN1, GADD45B, LAMA4, and MAPKAPK2 as predictors of TNF response in the optima cohort and validation cohorts. CI, confidence interval.CC BY · PubMed Central
Figure 5. Correlation between ex vivo probe confocal laser endomicroscopy findings and genes. Ex vivo data with mean value of the high threshold and low threshold on area intensity were used to link with selected genes. Three different samples, responder and nonresponder combined, responder, and nonresponder, were selected. Only significant Spearman correlation values are shown (P < .05). Red = positive correlation; blue = negative correlation. The ACTN1 expression value was 0 across all the samples for nonresponder and hence was not used. IBD, inflammatory bowel disease.
Figure 5. Correlation between ex vivo probe confocal laser endomicroscopy findings and genes. Ex vivo data with mean value of the high threshold and low threshold on area intensity were used to link with selected genes. Three different samples, responder and nonresponder combined, responder, and nonresponder, were selected. Only significant Spearman correlation values are shown (P < .05). Red = positive correlation; blue = negative correlation. The ACTN1 expression value was 0 across all the samples for nonresponder and hence was not used. IBD, inflammatory bowel disease.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 50

Metadata

Authors
Iacucci, M., Jeffery, L., Acharjee, A., Grisan, E., Buda, A., Nardone, O. M., Smith, S. C. L., Labarile, N., Zardo, D., Ungar, B., Hunter, S., Mao, R., Cannatelli, R., Shivaji, U. N., Parigi, T. L., Reynolds, G. M., Gkoutos, G. V., & Ghosh, S.
Affiliations
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • Queen Elizabeth Hospital Birmingham (GB)
  • University of Padua (IT)
  • Hospital of Prato (IT)
  • University of Birmingham (GB)
  • The First Affiliated Hospital, Sun Yat-sen University (CN)
  • NIHR Birmingham Biomedical Research Centre (GB)
Corresponding author
Iacucci, Marietta
Venue
Inflammatory Bowel Diseases
Published
2022-11-15
Volume
29
Issue
9
Pages
1409-1420
ISSN
  • 1078-0998 (ISSN-L)
  • 1536-4844
OpenAlex
W4309066082
Cited by
50
References
53
Citations by year
2026: 13 · 2025: 12 · 2024: 17 · 2023: 8
FWCI
5.58
Type
journal article
Language
en
Open access
Locations
  • Inflammatory Bowel Diseases (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
  • Research Open (London South Bank University) (acceptedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
Keywords
probe-based confocal laser endomicroscopy, inflammatory bowel disease
MeSH terms
Tumor Necrosis Factor Inhibitors, Biological Products, Biological Therapy, Colitis, Ulcerative, Crohn Disease, Fluoresceins, Humans, Lasers, Tumor Necrosis Factor-alpha, Inflammatory Bowel Diseases, Gene Expression, Adaptor Proteins, Signal Transducing, LIM Domain Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study. https://app.cochat.ai/papers/10.1093/ibd/izac233
The paper
Iacucci, M., Jeffery, L., Acharjee, A., Grisan, E., Buda, A., Nardone, O. M., Smith, S. C. L., Labarile, N., Zardo, D., Ungar, B., Hunter, S., Mao, R., Cannatelli, R., Shivaji, U. N., Parigi, T. L., Reynolds, G. M., Gkoutos, G. V., & Ghosh, S. (2023). Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izac233

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.